

Josã© M Matã©s

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2296221/publications.pdf>

Version: 2024-02-01

67
papers

8,941
citations

109321

35
h-index

110387

64
g-index

68
all docs

68
docs citations

68
times ranked

13827
citing authors

#	ARTICLE	IF	CITATIONS
1	Antioxidant enzymes and human diseases. <i>Clinical Biochemistry</i> , 1999, 32, 595-603.	1.9	1,656
2	Effects of antioxidant enzymes in the molecular control of reactive oxygen species toxicology. <i>Toxicology</i> , 2000, 153, 83-104.	4.2	1,219
3	Role of reactive oxygen species in apoptosis: implications for cancer therapy. <i>International Journal of Biochemistry and Cell Biology</i> , 2000, 32, 157-170.	2.8	639
4	The Metabolic Profile of Tumors Depends on Both the Responsible Genetic Lesion and Tissue Type. <i>Cell Metabolism</i> , 2012, 15, 157-170.	16.2	553
5	Analysis of Tumor Metabolism Reveals Mitochondrial Glucose Oxidation in Genetically Diverse Human Glioblastomas in the Mouse Brain <i>In Vivo</i> . <i>Cell Metabolism</i> , 2012, 15, 827-837.	16.2	459
6	Pyruvate carboxylase is required for glutamine-independent growth of tumor cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011, 108, 8674-8679.	7.1	411
7	Intracellular redox status and oxidative stress: implications for cell proliferation, apoptosis, and carcinogenesis. <i>Archives of Toxicology</i> , 2008, 82, 273-299.	4.2	387
8	MUC1 and HIF-1alpha Signaling Crosstalk Induces Anabolic Glucose Metabolism to Impart Gemcitabine Resistance to Pancreatic Cancer. <i>Cancer Cell</i> , 2017, 32, 71-87.e7.	16.8	373
9	Oxidative stress in apoptosis and cancer: an update. <i>Archives of Toxicology</i> , 2012, 86, 1649-1665.	4.2	290
10	Glutamine and its relationship with intracellular redox status, oxidative stress and cell proliferation/death. <i>International Journal of Biochemistry and Cell Biology</i> , 2002, 34, 439-458.	2.8	281
11	Roles of dioxins and heavy metals in cancer and neurological diseases using ROS-mediated mechanisms. <i>Free Radical Biology and Medicine</i> , 2010, 49, 1328-1341.	2.9	227
12	Antioxidant enzymes and their implications in pathophysiologic processes. <i>Frontiers in Bioscience - Landmark</i> , 1999, 4, d339-345.	3.0	199
13	Metabolic reprogramming induces resistance to anti-NOTCH1 therapies in T cell acute lymphoblastic leukemia. <i>Nature Medicine</i> , 2015, 21, 1182-1189.	30.7	180
14	Glutaminase Isoenzymes as Key Regulators in Metabolic and Oxidative Stress Against Cancer. <i>Current Molecular Medicine</i> , 2013, 13, 514-534.	1.3	161
15	Glutamine homeostasis and mitochondrial dynamics. <i>International Journal of Biochemistry and Cell Biology</i> , 2009, 41, 2051-2061.	2.8	123
16	Antisense glutaminase inhibition decreases glutathione antioxidant capacity and increases apoptosis in Ehrlich ascitic tumour cells. <i>FEBS Journal</i> , 2004, 271, 4298-4306.	0.2	118
17	Dysregulation of glutaminase and glutamine synthetase in cancer. <i>Cancer Letters</i> , 2019, 467, 29-39.	7.2	107
18	Co-expression of glutaminase K and L isoenzymes in human tumour cells. <i>Biochemical Journal</i> , 2005, 386, 535-542.	3.7	104

#	ARTICLE	IF	CITATIONS
19	Therapeutic targeting of glutaminolysis as an essential strategy to combat cancer. <i>Seminars in Cell and Developmental Biology</i> , 2020, 98, 34-43.	5.0	84
20	Both GLS silencing and GLS2 overexpression synergize with oxidative stress against proliferation of glioma cells. <i>Journal of Molecular Medicine</i> , 2014, 92, 277-290.	3.9	74
21	Glutaminase: A multifaceted protein not only involved in generating glutamate. <i>Neurochemistry International</i> , 2006, 48, 465-471.	3.8	69
22	Glutamine Addiction In Gliomas. <i>Neurochemical Research</i> , 2017, 42, 1735-1746.	3.3	64
23	Glutaminase isoenzymes in the metabolic therapy of cancer. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2018, 1870, 158-164.	7.4	63
24	Chemical and biological activity of free radical "scavengers"™ in allergic diseases. <i>Clinica Chimica Acta</i> , 2000, 296, 1-15.	1.1	62
25	Pathways from glutamine to apoptosis. <i>Frontiers in Bioscience - Landmark</i> , 2006, 11, 3164.	3.0	60
26	Antioxidant Enzymatic Activities in Human Blood Cells after an Allergic Reaction to Pollen or House Dust Mite. <i>Blood Cells, Molecules, and Diseases</i> , 1999, 25, 103-109.	1.4	59
27	A novel glutaminase isoform in mammalian tissues. <i>Neurochemistry International</i> , 2009, 55, 76-84.	3.8	56
28	Metabolic changes in cancer cells upon suppression of MYC. <i>Cancer & Metabolism</i> , 2013, 1, 7.	5.0	54
29	Natural Antioxidants: Therapeutic Prospects for Cancer and Neurological Diseases. <i>Mini-Reviews in Medicinal Chemistry</i> , 2009, 9, 1202-1214.	2.4	52
30	Expression of Gls and Gls2 glutaminase isoforms in astrocytes. <i>Glia</i> , 2015, 63, 365-382.	4.9	45
31	Mammalian Glutaminase Gls2 Gene Encodes Two Functional Alternative Transcripts by a Surrogate Promoter Usage Mechanism. <i>PLoS ONE</i> , 2012, 7, e38380.	2.5	44
32	Antisense glutaminase inhibition modifies the O ⁶ -GlcNAc pattern and flux through the hexosamine pathway in breast cancer cells. <i>Journal of Cellular Biochemistry</i> , 2008, 103, 800-811.	2.6	43
33	Expression of functional human glutaminase in baculovirus system: Affinity purification, kinetic and molecular characterization. <i>International Journal of Biochemistry and Cell Biology</i> , 2007, 39, 765-773.	2.8	39
34	Mammalian l-amino acid decarboxylases producing 1,4-diamines: analogies among differences. <i>Trends in Biochemical Sciences</i> , 1994, 19, 318-319.	7.5	38
35	Glutaminases regulate glutathione and oxidative stress in cancer. <i>Archives of Toxicology</i> , 2020, 94, 2603-2623.	4.2	38
36	Sulphur-containing non enzymatic antioxidants therapeutic tools against cancer. <i>Frontiers in Bioscience - Scholar</i> , 2012, S4, 722-748.	2.1	37

#	ARTICLE	IF	CITATIONS
37	Glutamate and Brain Glutaminases in Drug Addiction. <i>Neurochemical Research</i> , 2017, 42, 846-857.	3.3	35
38	New insights into brain glutaminases: Beyond their role on glutamatergic transmission. <i>Neurochemistry International</i> , 2009, 55, 64-70.	3.8	33
39	The Epithelial to Mesenchymal Transition Promotes Glutamine Independence by Suppressing GLS2 Expression. <i>Cancers</i> , 2019, 11, 1610.	3.7	31
40	Allergy to drugs: antioxidant enzymic activities, lipid peroxidation and protein oxidative damage in human blood. , 2000, 18, 77-84.		30
41	Genomic organization and transcriptional analysis of the human l-glutaminase gene. <i>Biochemical Journal</i> , 2003, 370, 771-784.	3.7	29
42	Chlorpheniramine inhibits the ornithine decarboxylase induction of Ehrlich carcinoma growing in vivo. <i>FEBS Letters</i> , 1992, 305, 260-264.	2.8	27
43	Simultaneous fluoremetric determination of intracellular polyamines separated by reversed-phase high-performance liquid chromatography. <i>Agents and Actions</i> , 1992, 36, 17-21.	0.7	26
44	Nuclear Translocation of Glutaminase GLS2 in Human Cancer Cells Associates with Proliferation Arrest and Differentiation. <i>Scientific Reports</i> , 2020, 10, 2259.	3.3	26
45	Metabolic Reprogramming of Cancer by Chemicals that Target Glutaminase Isoenzymes. <i>Current Medicinal Chemistry</i> , 2020, 27, 5317-5339.	2.4	26
46	Glutaminases. <i>Advances in Neurobiology</i> , 2016, 13, 133-171.	1.8	23
47	Altered ornithine metabolism in tumor-bearing mice. <i>Life Sciences</i> , 1989, 45, 1877-1884.	4.3	17
48	Antioxidant responses related to temozolomide resistance in glioblastoma. <i>Neurochemistry International</i> , 2021, 149, 105136.	3.8	17
49	Regulation by 1,4-diamines of the ornithine decarboxylase activity induced by ornithine in perfused tumor cells. <i>Biochemical Pharmacology</i> , 1991, 42, 1045-1052.	4.4	16
50	Anti-oxidant enzyme activities and expression and oxidative damage in patients with non-immediate reactions to drugs. <i>Clinical and Experimental Immunology</i> , 2006, 145, 287-295.	2.6	16
51	Histamine and serotonin inhibit induction of ornithine decarboxylase by ornithine in perfused Ehrlich ascites tumour cells. <i>FEBS Letters</i> , 1989, 250, 257-261.	2.8	15
52	Mammalian glutaminase isozymes in brain. <i>Metabolic Brain Disease</i> , 2013, 28, 133-137.	2.9	14
53	Inhibition of glutaminase expression increases Sp1 phosphorylation and Sp1/Sp3 transcriptional activity in Ehrlich tumor cells. <i>Cancer Letters</i> , 2005, 218, 91-98.	7.2	12
54	Identification of genes downregulated in tumor cells expressing antisense glutaminase mRNA by differential display. <i>Cancer Biology and Therapy</i> , 2006, 5, 54-58.	3.4	11

#	ARTICLE	IF	CITATIONS
55	Brain glutaminases. <i>Biomolecular Concepts</i> , 2010, 1, 3-15.	2.2	11
56	Glutaminase isoforms expression switches microRNA levels and oxidative status in glioblastoma cells. <i>Journal of Biomedical Science</i> , 2021, 28, 14.	7.0	11
57	Interrelationship between oxidative damage and antioxidant enzyme activities: an easy and rapid experimental approach. <i>Biochemical Education</i> , 2000, 28, 93-95.	0.1	10
58	Expression of different mitogen-regulated protein/proliferin mRNAs in Ehrlich carcinoma cells. <i>FEBS Letters</i> , 1994, 349, 343-348.	2.8	8
59	The induction of ornithine decarboxylase by ornithine takes place at post-transcriptional level in perfused Ehrlich carcinoma cells. <i>Cancer Letters</i> , 1992, 67, 187-192.	7.2	5
60	Interrelationship between oxidative damage and antioxidant enzyme activities: an easy and rapid experimental approach. <i>Biochemical Education</i> , 2000, 28, 93-95.	0.1	5
61	Canceromics Studies Unravel Tumor's Glutamine Addiction After Metabolic Reprogramming. , 2015, , 257-286.		5
62	Sensitisation of Ehrlich ascitic tumour cells to methotrexate by inhibiting glutaminase. <i>Anticancer Research</i> , 2005, 25, 3315-20.	1.1	5
63	Polyamine metabolism regulation by histamine and other biogenic amines in Ehrlich carcinoma cells. <i>Agents and Actions</i> , 1992, 36, C380-C383.	0.7	2
64	Structure/function relationship studies on the T/S residues 173-177 of rat ODC. <i>BBA - Proteins and Proteomics</i> , 1998, 1386, 113-120.	2.1	2
65	Antioxidant activity levels and oxidative stress as blood markers of allergic response to drugs. <i>Biochemistry and Cell Biology</i> , 2000, 78, 691-698.	2.0	2
66	Tumor Metabolome: Therapeutic Opportunities Targeting Cancer Metabolic Reprogramming. <i>Cancers</i> , 2021, 13, 314.	3.7	2
67	Chemical intermediates scavengers in the therapy of allergic diseases. <i>Research on Chemical Intermediates</i> , 2001, 27, 297-304.	2.7	0